These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19652076)

  • 1. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
    Jeha S; Razzouk B; Rytting M; Rheingold S; Albano E; Kadota R; Luchtman-Jones L; Bomgaars L; Gaynon P; Goldman S; Ritchey K; Arceci R; Altman A; Stine K; Steinherz L; Steinherz P
    J Clin Oncol; 2009 Sep; 27(26):4392-7. PubMed ID: 19652076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
    J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.
    Suzuki T; Yamauchi T; Ando K; Nagai T; Kakihana K; Miyata Y; Uchida T; Tabata Y; Ogura M
    Jpn J Clin Oncol; 2013 Dec; 43(12):1177-83. PubMed ID: 24130086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
    Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
    Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia].
    Suo P; Zhang LP; Wu J; Lu AD; Wang B; Zuo YX; Cheng YF; Liu GL
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):444-7. PubMed ID: 23791059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
    Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
    Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
    Locke FL; Artz A; Rich E; Zhang Y; van Besien K; Stock W
    Bone Marrow Transplant; 2010 Dec; 45(12):1692-8. PubMed ID: 20208570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
    Foster MC; Amin C; Voorhees PM; van Deventer HW; Richards KL; Ivanova A; Whitman J; Chiu WM; Barr ND; Shea T
    Leuk Lymphoma; 2012 Jul; 53(7):1331-7. PubMed ID: 22149206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.
    Liu AP; Lee V; Li CK; Ha SY; Chiang AK
    Ann Hematol; 2016 Feb; 95(3):501-7. PubMed ID: 26666536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
    Shukla N; Kobos R; Renaud T; Steinherz LJ; Steinherz PG
    Pediatr Blood Cancer; 2014 Mar; 61(3):431-5. PubMed ID: 24115731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Hijiya N; Thomson B; Isakoff MS; Silverman LB; Steinherz PG; Borowitz MJ; Kadota R; Cooper T; Shen V; Dahl G; Thottassery JV; Jeha S; Maloney K; Paul JA; Barry E; Carroll WL; Gaynon PS
    Blood; 2011 Dec; 118(23):6043-9. PubMed ID: 21967976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia.
    Tischer J; Stemmler HJ; Engel N; Hubmann M; Fritsch S; Prevalsek D; Schulz C; Zoellner AK; Bücklein V; Hill W; Ledderose G; Hausmann A
    Ann Hematol; 2013 Oct; 92(10):1379-88. PubMed ID: 23928857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
    Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clofarabine as a bridge to hematopoietic stem cell transplant.
    Thomas CM; Ippoliti C; Roboz GJ; Feldman E; Savva D; James S; van Besien K
    Leuk Lymphoma; 2017 Jan; 58(1):230-232. PubMed ID: 27240704
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
    Nabhan C; Davis N; Bitran JD; Galvez A; Fried W; Tolzien K; Foss S; Dewey WM; Venugopal P
    Cancer; 2011 Apr; 117(7):1490-7. PubMed ID: 21425150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
    Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
    Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.
    Loeffler C; Kapp M; Grigoleit GU; Mielke S; Loeffler J; Heuschmann PU; Malzahn U; Hupp E; Einsele H; Stuhler G
    Leuk Lymphoma; 2015; 56(12):3365-9. PubMed ID: 26014275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
    Jeha S; Gandhi V; Chan KW; McDonald L; Ramirez I; Madden R; Rytting M; Brandt M; Keating M; Plunkett W; Kantarjian H
    Blood; 2004 Feb; 103(3):784-9. PubMed ID: 14551141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
    Foss FM; Parker T
    Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.